Literature DB >> 2945688

Pharmacokinetics and effect on blood pressure of doxazosin in normal subjects and patients with renal failure.

R V Carlson, R R Bailey, E J Begg, M G Cowlishaw, J R Sharman.   

Abstract

The antihypertensive efficacy and pharmacokinetics of a single 1 mg oral dose of doxazosin were investigated in five healthy male volunteers, six patients with renal failure not on hemodialysis, and four patients with end-stage renal failure studied between two hemodialyses. The dialyzability of doxazosin was studied in five patients. The maximum fall in blood pressure of both volunteers and patients occurred between 4 and 8 hours. In four of five volunteers the blood pressure had returned to baseline within 10 to 12 hours, whereas in the patients with renal failure it took as long as 72 hours. Maximum plasma concentrations were reached in 2.6 to 3.6 hours. The mean AUC did not differ significantly between the groups. The mean (SE) elimination t1/2 was 12.6 hours (3.3) in the volunteers and 13.3 hours (1.8) in the patients with renal insufficiency (not significant). Doxazosin was not appreciably dialyzable.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2945688     DOI: 10.1038/clpt.1986.224

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

1.  Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation.

Authors:  M Chung; V Vashi; J Puente; M Sweeney; P Meredith
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

2.  Comparison of the antagonistic activity of tamsulosin and doxazosin at vascular alpha 1-adrenoceptors in humans.

Authors:  K Harada; M Ohmori; A Fujimura
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

Review 3.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

4.  The pharmacokinetics of doxazosin in patients with hypertension and renal impairment.

Authors:  R M Oliver; J W Upward; A G Dewhurst; R Honeywell; A G Renwick; D G Waller
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

Review 5.  Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.

Authors:  R A Young; R N Brogden
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

Review 6.  Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia.

Authors:  B Fulton; A J Wagstaff; E M Sorkin
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

7.  Bunazosin in patients with impaired hepatic or renal function.

Authors:  A Halabi; A Nokhodian; W Kirch
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jul-Sep       Impact factor: 2.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.